keyword
MENU ▼
Read by QxMD icon Read
search

oligometastasis

keyword
https://read.qxmd.com/read/30746198/surgery-of-primary-non-small-cell-lung-cancer-with-oligometastasis-analysis-of-172-cases
#1
Zhe Wang, Shu-Geng Gao, Qi Xue, Xiao-Tong Guo, Li-Xu Wang, Xin Yu, Yi-Kun Yang, Ju-Wei Mu
Background: Previous studies have demonstrated that survival of patients with non-small cell lung cancer (NSCLC) with oligometastasis may benefit from local treatment. The purpose of this study was to compare the efficacy of local surgical treatment with systematic chemoradiotherapy in NSCLC with oligometastasis. Methods: Data from a total of 172 patients with NSCLC with oligometastasis were collected at our Cancer Hospital from January 2006 to December 2016. The patients were divided into two groups: group A (82 cases) underwent primary surgical treatment and adjuvant chemotherapy was performed after operation, while group B (90 cases) received systematic chemotherapy and local radiotherapy...
December 2018: Journal of Thoracic Disease
https://read.qxmd.com/read/30678111/stereotactic-radiotherapy-for-oligometastasis
#2
REVIEW
Sotaro Otake, Taichiro Goto
Oligometastatic disease is defined as "a condition with a few metastases arising from tumors that have not acquired a potential for widespread metastases." Its behavior suggests a transitional malignant state somewhere between localized and metastatic cancer. Treatment of oligometastatic disease is expected to achieve long-term local control and to improve survival. Historically, patients with oligometastases have often undergone surgical resection since it was anecdotally believed that surgical resection could result in progression-free or overall survival benefits...
January 23, 2019: Cancers
https://read.qxmd.com/read/30617554/impact-of-ga-68-psma-pet-ct-on-management-in-prostate-cancer-patients-with-very-early-biochemical-recurrence-after-radical-prostatectomy
#3
Usman Bashir, Alison Tree, Erik Mayer, Daniel Levine, Chris Parker, David Dearnaley, Wim J G Oyen
PURPOSE: With the availability of ultra-sensitive PSA assays, early biochemical relapse (eBCR) of prostate cancer is increasingly being detected at values much lower than the conventional threshold of 0.2 ng/ml. Accurate localisation of disease in this setting may allow treatment modification and improved outcomes, especially in patients with pelvis-confined or extra-pelvic oligometastasis (defined as up to three pelvic nodal or distant sites). We aimed to measure the detection rate of [68]Ga-PSMA-HBNED-CC (PSMA)-PET/CT and its influence on patient management in eBCR of prostate cancer following radical prostatectomy (RP)...
January 8, 2019: European Journal of Nuclear Medicine and Molecular Imaging
https://read.qxmd.com/read/30591352/oligometastatic-prostate-cancer-is-it-only-a-matter-of-perspective
#4
EDITORIAL
Giuseppe Di Lorenzo, Carlo Buonerba
The oligometastatic state of prostate cancer (PC) is of clinical importance because of its implications for surgery, radiotherapy, and systemic therapy. Improving the definition of oligometastatic PC will offer an opportunity to discover whether disease burden is a clinically meaningful variable or if oligometastasis is a distinctive state of PC with a largely unexplored biological background.
December 24, 2018: European Urology
https://read.qxmd.com/read/30509099/recurrent-oligometastatic-transitional-cell-bladder-carcinoma-is-there-room-for-radiotherapy
#5
M Augugliaro, G Marvaso, D Ciardo, D Zerini, G Riva, E Rondi, S Vigorito, S Comi, O De Cobelli, R Orecchia, B Alicja Jereczek-Fossa
The aim of our study was to retrospectively report on radiotherapy (RT) in the oligometastastic recurrence of bladder cancer. Thirteen patients treated for low-volume metastatic transitional cell urinary bladder carcinoma (TCC) were reviewed. The primary endpoint was to evaluate the safety and efficacy of RT, proposed as an alternative to systemic treatment and/or to defer the start of a systemic therapy. Inclusion criteria for our retrospective study were as follows: patients that received RT (without other local/systemic therapy) for oligometastatic TCC with lymph node, bone, lung lesions or local recurrence...
September 4, 2018: Neoplasma
https://read.qxmd.com/read/30407123/real-time-tumor-tracking-radiotherapy-and-general-stereotactic-body-radiotherapy-for-adrenal-metastasis-in-patients-with-oligometastasis
#6
Norio Katoh, Hiroshi Onishi, Yusuke Uchinami, Tetsuya Inoue, Kengo Kuriyama, Kentaro Nishioka, Shinichi Shimizu, Takafumi Komiyama, Naoki Miyamoto, Hiroki Shirato
BACKGROUND: Precise local radiotherapy for adrenal metastasis can prolong the useful life of patients with oligometastasis. The aim of this retrospective, 2-center study was to establish the safety and effectiveness of real-time tumor-tracking radiotherapy and general stereotactic body radiotherapy in treating patients with adrenal metastatic tumors. MATERIALS AND METHODS: Thirteen lesions in 12 patients were treated with real-time tumor-tracking radiotherapy (48 Gy in 8 fractions over 2 weeks) and 8 lesions in 8 patients were treated with general stereotactic body radiotherapy (40-50 Gy in 5-8 fractions over 2 weeks or 60-70 Gy in 10 fractions over 2 weeks)...
January 1, 2018: Technology in Cancer Research & Treatment
https://read.qxmd.com/read/30363448/emerging-role-of-cytoreductive-prostatectomy-in-patients-with-metastatic-disease
#7
REVIEW
Yasmeen Jaber, Chad A Reichard, Brian F Chapin
Traditionally, systemic androgen deprivation therapy (ADT) has been the primary treatment modality in metastatic prostate cancer (mPCa) while treatment of the primary tumor has been reserved for patients with clinically localized disease. Emerging data suggests that treating the primary tumor in patients with metastatic disease may provide a survival benefit. However, these studies are fraught with selection bias towards patients with favorable disease characteristics. Despite these limitations, clinicians are becoming increasingly interested in consolidative treatment of the primary tumor in this setting...
September 2018: Translational Andrology and Urology
https://read.qxmd.com/read/30301603/sec23a-mediates-mir-200c-augmented-oligometastatic-to-polymetastatic-progression
#8
Zhiwei Sun, Shixia Zhou, Junling Tang, Ting Ye, Jingyuan Li, Doudou Liu, Jian Zhou, Jianyu Wang, H Rosie Xing
BACKGROUND: Cancer treatment is based on tumor staging. Curative intent is only applied to localized tumors. Recent studies show that oligometastatic patients who have limited number of metastases may benefit from metastasis-directed local treatments to achieve long-term survival. However, mechanisms underlying oligometastatic to polymetastatic progression remains elusive. METHODS: The effects of miR-200c and Sec23a on tumor metastasis were verified both in vitro and in vivo...
October 6, 2018: EBioMedicine
https://read.qxmd.com/read/30296648/treatment-outcomes-of-breast-cancer-liver-metastasis-treated-with-stereotactic-body-radiotherapy
#9
Cem Onal, Ozan Cem Guler, Berna Akkus Yildirim
BACKGROUND: To assess the outcomes of breast cancer liver metastasis (BCLM) treated with stereotactic body radiotherapy (SBRT) and systemic treatment. MATERIALS AND METHODS: Patients with oligometastasis at the time of liver metastasis (LM) or who became oligometastatic (≤5 metastases) after systemic treatment were assessed. Twenty-nine liver metastatic lesions were treated with a total of 54 Gy delivered in 3 fractions. The local control (LC), overall survival (OS), and progression-free survival (PFS) rates were calculated using Kaplan-Meier analyses...
December 2018: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/30260759/the-46th-david-a-karnofsky-memorial-award-lecture-oligometastasis-from-conception-to-treatment
#10
Ralph R Weichselbaum
Metastasis from most adult solid tumors generally has been considered to be widespread and incurable. Here, I present clinical and molecular data to support the hypothesis that some metastases are limited in number and pace and are curable with ablative therapies. I advance the hypothesis that immunotherapy combined with radiotherapy may be a general strategy to increase the number of patients with metastatic cancer amenable to cure. I further suggest that, in the context of ablative radiotherapy, the potential synergies between immunotherapy and radiotherapy are principally within the local tumor microenvironment and require treatment of all or most sites of metastatic disease...
September 27, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30211037/the-8-th-lung-cancer-tnm-classification-and-clinical-staging-system-review-of-the-changes-and-clinical-implications
#11
REVIEW
Wanyin Lim, Carole A Ridge, Andrew G Nicholson, Saeed Mirsadraee
Lung cancer is the leading cause of cancer death in both men and women. Clinical staging plays a crucial role in predicting survivor as well as influencing management option in lung cancer patients. Guidelines are constantly being reviewed as more data becomes available to provide the most accurate prognostic markers, hence aiding in the clinical detection and staging of lung cancer. Since its introduction in the 1970s, the TNM staging has undergone significant revisions with the latest, 8th edition, being effective internationally from 2018...
August 2018: Quantitative Imaging in Medicine and Surgery
https://read.qxmd.com/read/30076479/stereotactic-body-radiotherapy-for-lung-oligometastases-impacts-on-systemic-treatment-free-survival-a-cohort-study
#12
Rosario Mazzola, Sergio Fersino, Giuseppe Ferrera, Giovanni Targher, Vanessa Figlia, Luca Triggiani, Nadia Pasinetti, Antonio Lo Casto, Ruggero Ruggieri, Stefano Maria Magrini, Filippo Alongi
To analyze the impact of SBRT on systemic treatment-free survival in patients affected by lung oligometastases. Inclusion criteria of the study were (a) KPS > 70, (b) 1-5 lung oligometastases underwent SBRT with a BED ≥ 100 Gy, (c) absence of extra-thoracic disease, (d) controlled primary tumor, (e) metachronous oligorecurrences for whom SBRT was adopted as primary treatment option, (f) oligoprogressive lung metastases who progressed following a disease remission after a first-line therapy, (g) oligopersistent disease after systemic therapy, and (h) at least 6 months of follow-up post-SBRT...
August 4, 2018: Medical Oncology
https://read.qxmd.com/read/29939888/convex-probe-ebus-guided-fiducial-placement-for-malignant-central-lung-lesions
#13
Adnan Majid, Atul Palkar, Fayez Kheir, Daniel Alape, Sebastian Fernandez-Bussy, Joseph Aronovitz, Jorge Guerrero, Sidhu Gangadharan, Michael Kent, Richard Whyte, Erik Folch
BACKGROUND: Stereotactic body radiotherapy (SBRT) had become a therapeutic modality in patients with primary tumors, locally recurrent as well as oligometastasis involving the lung. Some modalities of SBRT require fiducial marker (FM) for dynamic tumor tracking. Previous studies have focused on evaluating bronchoscopic-guided FM placement for peripheral lung nodules. We describe the safety and feasibility of placing FM using real-time convex probe endobronchial ultrasound (CP-EBUS) for SBRT in patients with centrally located hilar/mediastinal masses or lymph nodes...
June 22, 2018: Journal of Bronchology & Interventional Pulmonology
https://read.qxmd.com/read/29933483/-lung-resection-after-definitive-and-neo-adjuvant-chemoradiation-for-stage-iiia-b-locally-advanced-non-small-cell-lung-cancer-a-retrospective-analysis
#14
Waldemar Schreiner, Sofiia Gavrychenkova, Wojciech Dudek, Sebastian Lettmaier, Ralf Rieker, Rainer Fietkau, Horia Sirbu
BACKGROUND: The outcomes of so called "salvage" resections after definitive chemoradiation vs. curative resections after neoadjuvant chemoradiation therapy (IT-resection) in patients with stage IIIA/B locally advanced non-small cell lung cancer have rarely been compared. The aim of our study was to compare perioperative results, postoperative and recurrence-free survival and to identify relevant prognostic survival factors for both therapy strategies. PATIENTS AND METHODS: Between June 2008 and May 2017, 43 patients underwent pulmonary resection following induction therapy (group 1) and 14 patients underwent salvage resection after definitive chemoradiation (group 2)...
June 2018: Zentralblatt Für Chirurgie
https://read.qxmd.com/read/29916497/eus-guided-radiofrequency-ablation-for-a-left-adrenal-oligometastasis-of-an-esophageal-adenocarcinoma
#15
Akin Inderson, Marije Slingerland, Arantza Farina Sarasqueta, Wobbe O de Steur, Jurjen J Boonstra
No abstract text is available yet for this article.
May 2018: VideoGIE: an official video journal of the American Society for Gastrointestinal Endoscopy
https://read.qxmd.com/read/29876615/-oligometastases-of-neuroendocrine-tumors-extent-of-surgery
#16
REVIEW
F Bösch, J Werner, M K Angele, M O Guba
Neuroendocrine tumors (NETs) are rare neoplasms, which represent complex challenges in diagnosis and treatment. Even in the metastatic stage there are important differences in the type of tumor in comparison to gastrointestinal and pancreatic adenocarcinomas. Therefore, the disease courses are substantially different depending on the grade of differentiation. Even in the metastatic stage the 5‑year survival rates of G1 tumors is up to 83%. Approximately 20% of small intestine NETs additionally show hormone activity, which can compromise survival and the quality of life...
June 6, 2018: Der Chirurg; Zeitschrift Für Alle Gebiete der Operativen Medizen
https://read.qxmd.com/read/29756301/oligometastatic-status-as-predictor-of-survival-in-metastatic-human-papillomavirus-positive-oropharyngeal-carcinoma
#17
William G Albergotti, Shira Abberbock, Fasil Mathews, Robert L Ferris, Jonas T Johnson, Umamaheswar Duvvuri, Seungwon Kim
BACKGROUND: Oligometastasis is a good prognostic indicator when compared to widely metastatic disease in malignancies of other organ systems. We hypothesized that oligometastasis in human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (SCC) would be associated with better overall survival. METHODS: This is a retrospective review of all HPV-positive oropharyngeal SCC treated at one center with at least 1-year of follow-up. Patients were stratified into 2 cohorts: oligometastasis (1-2 metastases, confined to 1 organ system) or polymetastasis (>2 metastases or multiple organ involvement) with cohorts compared for time to distant metastasis and overall survival after metastasis...
August 2018: Head & Neck
https://read.qxmd.com/read/29728604/integrated-molecular-subtyping-defines-a-curable-oligometastatic-state-in-colorectal-liver-metastasis
#18
Sean P Pitroda, Nikolai N Khodarev, Lei Huang, Abhineet Uppal, Sean C Wightman, Sabha Ganai, Nora Joseph, Jason Pitt, Miguel Brown, Martin Forde, Kathy Mangold, Lai Xue, Christopher Weber, Jeremy P Segal, Sabah Kadri, Melinda E Stack, Sajid Khan, Philip Paty, Karen Kaul, Jorge Andrade, Kevin P White, Mark Talamonti, Mitchell C Posner, Samuel Hellman, Ralph R Weichselbaum
The oligometastasis hypothesis suggests a spectrum of metastatic virulence where some metastases are limited in extent and curable with focal therapies. A subset of patients with metastatic colorectal cancer achieves prolonged survival after resection of liver metastases consistent with oligometastasis. Here we define three robust subtypes of de novo colorectal liver metastasis through integrative molecular analysis. Patients with metastases exhibiting MSI-independent immune activation experience the most favorable survival...
May 4, 2018: Nature Communications
https://read.qxmd.com/read/29707323/long-term-survival-without-surgery-in-nsclc-patients-with-synchronous-brain-oligometastasis-systemic-chemotherapy-revisited
#19
Jun Sato, Hidehito Horinouchi, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Yuichiro Ohe
Background: Among patients with metastatic non-small-cell lung cancer (NSCLC), patients with TNM stage N0 to N1 and brain oligometastases (BOM) (less than 5 metastases) as the sole distant lesion (N0-1 BOM) who receive surgical treatments for the primary and metastatic sites reportedly have a better prognosis. Little data is available regarding the outcomes of patients treated with only systemic chemotherapy for the primary site and definitive treatment for synchronous BOM, compared with the outcomes of patients receiving surgical treatment for the primary site...
March 2018: Journal of Thoracic Disease
https://read.qxmd.com/read/29676372/urothelial-carcinoma-of-urinary-bladder-with-exclusive-heterologous-component-of-epithelioid-rhabdomyosarcoma-at-metastatic-site
#20
Poojan Agarwal, Sunil Pasricha, Gurudutt Gupta, Anila Sharma, Anurag Mehta
Urothelial carcinoma of urinary bladder with divergent differentiation into rhabdomyosarcoma (RMS) is an extremely uncommon aggressive phenomenon. We present a case of a 74-year-old male with bladder carcinoma which metastasized to the abdominal wall as epithelioid RMS. To the best knowledge of our literature searches, an oligometastasis of exclusive heterologous component has not been described before. The clinical, radiological, and immunohistochemistry profile of the patient supported the monoclonal nature of the tumor...
April 2018: Indian Journal of Pathology & Microbiology
keyword
keyword
110570
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"